内皮素受体拮抗剂治疗肾脏疾病的研究进展  

Advances on endothelin receptor antagonists in the treatment of kidney diseases

作　　者：朱岩 虞婧婷(综述) 朱斌(审校) ZHU Yan;YU Jingting;ZHU Bin(Zhejiang Chinese Medical University,Hangzhou 310000,China;Department of Nephrology,Zhejiang Provincial People's Hospital,Hangzhou 310000,China)

机构地区：[1]浙江中医药大学,杭州310000 [2]浙江省人民医院肾内科

出　　处：《肾脏病与透析肾移植杂志》2024年第4期367-371,共5页Chinese Journal of Nephrology,Dialysis & Transplantation

基　　金：浙江省中医药管理局共建科技计划(GZY-ZJ-KJ-23002);浙江省医药卫生科技计划(2024KY037)。

摘　　要：内皮素与肾脏疾病密切相关,激活内皮素受体A后促进血管收缩,引起肾脏炎症、纤维化和细胞增殖,导致肾损伤,通过拮抗内皮素受体可以保护肾功能。目前越来越多的研究证实,内皮素受体拮抗剂能减少多种肾脏疾病的尿蛋白,保护肾功能,本文就内皮素拮抗剂治疗肾脏疾病的进展作一简述。Endothelin is closely associated with kidney diseases.Activation of endothelin receptor A promotes vasoconstriction,inflammation,fibrosis,and cell proliferation,leading to kidney damage.By antagonizing the endothelin receptors,renal function can be protected.Currently,endothelin receptor antagonists are primarily used to treat pulmonary arterial hypertension.However,numerous clinical trials have confirmed that endothelin receptor antagonists are significantly effective in reducing proteinuria and protecting renal function.They are promising as a new type of medication for the treatment of various kidney diseases.

关 键 词：内皮素受体拮抗剂 肾小球疾病 肾血管疾病 

分 类 号：R692[医药卫生—泌尿科学]